Biogen shares spike as execs complete a delayed pitch for their controversial Alzheimer's drug — the next move belongs to the FDA
Biogen is stepping out onto the high wire today, reporting that the team working on the controversial Alzheimer’s drug aducanumab has now completed their submission …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
